Market Closed -
Nasdaq
04:00:00 2024-05-08 pm EDT
|
5-day change
|
1st Jan Change
|
12.66
USD
|
-7.25%
|
|
-23.78%
|
0.00%
|
Fiscal Period: December |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
545.8
|
-
|
-
|
Enterprise Value (EV)
1 |
349.2
|
404.1
|
340.4
|
P/E ratio
|
-3.98
x
|
-3.2
x
|
-2.81
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
146
x
|
109
x
|
65.5
x
|
EV / Revenue
|
93.1
x
|
80.8
x
|
40.8
x
|
EV / EBITDA
|
-2.75
x
|
-2.05
x
|
-1.61
x
|
EV / FCF
|
-2.89
x
|
-2.16
x
|
-
|
FCF Yield
|
-34.6%
|
-46.3%
|
-
|
Price to Book
|
5.02
x
|
-6.92
x
|
97.4
x
|
Nbr of stocks (in thousands)
|
43,115
|
-
|
-
|
Reference price
2 |
12.66
|
12.66
|
12.66
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
3.75
|
5
|
8.333
|
EBITDA
1 |
-
|
-60.7
|
-127.2
|
-197.5
|
-211.7
|
EBIT
1 |
-
|
-62.41
|
-141
|
-199.6
|
-211.1
|
Operating Margin
|
-
|
-
|
-3,759.15%
|
-3,991.87%
|
-2,532.61%
|
Earnings before Tax (EBT)
1 |
-
|
-60.37
|
-129.8
|
-189.6
|
-217.1
|
Net income
1 |
-28.89
|
-60.37
|
-129.8
|
-198.5
|
-217.1
|
Net margin
|
-
|
-
|
-3,460.8%
|
-3,970.07%
|
-2,605.22%
|
EPS
2 |
-13.94
|
-89.61
|
-3.180
|
-3.956
|
-4.510
|
Free Cash Flow
1 |
-
|
-53.03
|
-121
|
-187
|
-
|
FCF margin
|
-
|
-
|
-3,226.67%
|
-3,740%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/5/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-20.92
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.38
|
-32
|
-37
|
-39
|
-42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-75.82
|
-0.8000
|
-0.7500
|
-0.7700
|
-0.8600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
197
|
142
|
205
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-53
|
-121
|
-187
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-53.6%
|
-670%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-47.1%
|
-44.8%
|
-
|
Assets
1 |
-
|
-
|
275.7
|
443.2
|
-
|
Book Value Per Share
2 |
-
|
-
|
2.520
|
-1.830
|
0.1300
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.62
|
7
|
10
|
-
|
Capex / Sales
|
-
|
-
|
186.67%
|
200%
|
-
|
Announcement Date
|
10/5/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
12.66
USD Average target price
42.75
USD Spread / Average Target +237.68% Consensus |
1st Jan change
|
Capi.
|
---|
| 0.00% | 589M | | +22.56% | 46.4B | | -1.51% | 41.75B | | +48.83% | 41.37B | | -3.42% | 29.71B | | +10.13% | 26.01B | | -20.44% | 19.52B | | +26.45% | 12.43B | | -0.14% | 12.18B | | -0.47% | 12.13B |
Other Biotechnology & Medical Research
|